Related Experiment Video
Updated: Jun 29, 2025

09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
17.4K
Polyvalent immunoglobulin use: Issues between good use, economic constraints and shortages over 25 years
Q Perrier1, V Tuloup2, C Chevallier-Brilloit2
1Univ. Grenoble Alpes, INSERM, LBFA, U1055, Pharmacy department, Grenoble Alpes University Hospital, Grenoble, France.
European Journal of Internal Medicine
|March 26, 2024
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
Humoral Immune Responses
72.7K
Overview
72.7K
Immunodeficiency Diseases
937
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
937
Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
Cross-reactivity
31.1K
Overview
31.1K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
57
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
57

